|
|
||||||||
From the Departments of Neurology (Dr Markley), Medicine (Dr. Cheronis), and the School of Pharmacy (Dr. Piepho). University of Colorado Health Sciences Center, Denver, CO.
We conducted a double-blind, placebo-controlled crossover study of verapamil HCI in the prophylaxis of chronic migraine headaches. Verapamil significantly reduced both headache frequency and duration with few side effects. The drug may be useful for a segment of the migraine population refractory to other prophylactic agents or for those who cannot tolerate the side effects of other drugs.
Address correspondence and reprint requests to Dr. Markley, Department of Neurology, Worcester Memorial Hospital, 119 Belmont St., Worcester, MA 01605.
Supported by General Clinical Research Centers Grant number RR00051-22 from the National Institutes of Health to the University of Colorado Health Sciences Center.
Presented in part at the thirty-fifth annual meeting of the American Academy of Neurology, San Diego, CA, April 1983.
Accepted for publication November 23, 1983.
This article has been cited by other articles:
![]() |
K.M.A. Welch Drug Therapy of Migraine N. Engl. J. Med., November 11, 1993; 329(20): 1476 - 1483. [Full Text] |
||||
![]() |
J. F. Rothrock, P. Walicke, M. R. Swenson, P. D. Lyden, and W. R. Logan Migrainous Stroke Arch Neurol, January 1, 1988; 45(1): 63 - 67. [Abstract] [PDF] |
||||
![]() |
J. S. MEYER Calcium Channel Blockers in the Prophylactic Treatment of Vascular Headache Ann Intern Med, March 1, 1985; 102(3): 395 - 397. [Abstract] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |